Abstract: An aircraft part with a door for accessing inside an aircraft and a fuselage part includes a cavity between an upstream edge of the door in the closed position and a downstream edge of the fuselage part, the cavity opening to the outside of the aircraft part and having a bottom connected to the upstream edge of the door and to the downstream edge of the fuselage part. The aircraft part includes a chamfer on the outer face of an outer plate of the door at the upstream edge of the door, as well as possibly other technical features such as a sharp ridge and/or an add-on component, allowing for reducing noise generated by the cavity.

Abstract: A method for characterizing a mechanical part making it possible to evaluate the residual stresses in the part, as well as a method for constructing a predictive model and a non-destructive testing method making it possible to easily test such a part, the characterizing method including the following steps: measuring geometrical information of the part in a first state, physically transforming the part between the first state and a second state, measuring geometrical information of the part in its second state, determining the displacement field between the first state and the second state of the part by a digital image correlation method and obtaining the deformation field between the first state and the second state of the part, determining the stress field in the second state of the part by a finite element simulation method.

Abstract: The invention relates to a medical compression clip (1) capable of imparting compression to two bone fractions and/or to biological tissues, the clip comprising at least two legs (2, 3) extending from a transverse bridge, at least one leg (2) occupying a naturally converging position directed towards the other leg (3), the converging leg (2) being capable of being subjected to temporary elastic deformation and of returning naturally to its converging position, the clip being provided with deformation means enabling a force opposing convergence to be exerted on said at least one converging leg (2, 3) by means of an external tool, the deformation means being formed by a reception member for receiving the external tool, the clip (1) being characterized in that the reception member is arranged within the transverse bridge in such a manner that the external tool can bear against and along said converging leg (2, 3). Medical clips.

Abstract: The present invention relates to a novel fusion protein with the formula X-Y, or Y-X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof.

Abstract: The present invention relates to a novel fusion protein with the formula X-Y, or Y-X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof.

Abstract: The present invention concerns new recombinant viral vaccines. In particular the present invention provides combination products that comprise recombinant viral vectors and specific compounds able to improve the immune response raised in vivo by said recombinant viral vectors.

Abstract: The present invention relates to a novel fusion protein with the formula X-Y, or Y-X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof.

Abstract: Compositions containing one or more early polypeptide(s) of human papillomavirus (HPV)-16 or a nucleic acid encoding one or more early polypeptide(s) of HPV-16 are useful for preventing or treating an infection or a pathological condition caused by at least one papillomavirus other than HPV-16; the subject compositions are of very special interest in immunotherapy, in particular for preventing or treating HPV persistent infections that might promote cervical intraepithelial neoplasia (CIN) and ultimately cervical cancer.

Abstract: Compositions containing one or more early polypeptide(s) of human papillomavirus (HPV)-18 or a nucleic acid encoding one or more early polypeptide(s) of HPV-18 are useful for preventing or treating an infection or a pathological condition caused by at least one papillomavirus other than HPV-18; the subject compositions are of very special interest in immunotherapy, in particular for preventing or treating HPV persistent infections that might promote cervical intraepithelial neoplasia (CIN) and ultimately cervical cancer.

Abstract: The present invention provides a novel adjuvant for nucleic acid vaccines, and in particular the present invention provides nucleic acid vaccines that comprise, or are administered in association with PPD. The present invention also provides methods to improve the therapeutic efficacy of nucleic acid vaccines.

Abstract: The present invention relates to a novel fusion protein with the formula X—Y, or Y—X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X; it also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule; it also relates to infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles; is also relates to a method for recombinantly producing such a fusion protein; and, lastly, it also relates to a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof.

Abstract: The present invention relates to a novel fusion protein with the formula X—Y, or Y—X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof.

Abstract: The present invention concerns a poxviral particle having a targeted infection specificity conferred by an heterologous ligand moiety present at the surface of said poxviral particle and capable of specifically recognizing and binding to an anti-ligand molecule localized at the surface of target cells. The present invention further relates to a vector comprising a nucleotide sequence encoding a chimeric polypeptide including such an heterologous ligand moiety and all or part of a natural poxviral surface polypeptide. The present invention additionally concerns compositions comprising said poxviral particle or said vector as well as their use for therapeutic and prophylactic purposes. The invention is of very special interest in gene therapy applications, in particular in preventing or treating cancer in mammals.

Abstract: The present invention concerns a poxviral particle having a targeted infection specificity conferred by an heterologous ligand moiety present at the surface of said poxviral particle and capable of specifically recognizing and binding to an anti-ligand molecule localized at the surface of target cells. The present invention further relates to a vector comprising a nucleotide sequence encoding a chimeric polypeptide including such an heterologous ligand moiety and all or part of a natural poxviral surface polypeptide. The present invention additionally concerns compositions comprising said poxviral particle or said vector as well as their use for therapeutic and prophylactic purposes. The invention is of very special interest in gene therapy applications, in particular in preventing or treating cancer in mammals.

Abstract: The present invention relates to a novel fusion protein with the formula X—Y, or Y—X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof.

Abstract: The invention concerns a biological material for preparing pharmaceutical compositions for treating mammals including either a nucleic acid sequence, containing at least a gene of therapeutic interest and elements expressing the gene in vivo in target cells genetically modified by one such nucleic sequence, or at least a target cell not producing antibodies naturally, genetically modified in vitro by at least one such nucleic acid sequence. The gene of therapeutic interest codes for all or part of an antibody expressed at the surface of the target cell, and such an antibody is capable of fixing itself to a polypeptide present at the surface of a cytotoxic effector cell or a T lymphocyte helper involved in the process activating such a cell.

Abstract: The present invention concerns a poxviral particle having a targeted infection specificity conferred by an heterologous ligand moiety present at the surface of said poxviral particle and capable of specifically recognizing and binding to an anti-ligand molecule localized at the surface of target cells. The present invention further relates to a vector comprising a nucleotide sequence encoding a chimeric polypeptide including such an heterologous ligand moiety and all or part of a natural poxviral surface polypeptide. The present invention additionally concerns compositions comprising said poxviral particle or said vector as well as their use for therapeutic and prophylactic purposes.

Abstract: The present invention relates to a novel fusion protein with the formula X—Y, or Y—X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X; it also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule; it also relates to infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles; is also relates to a method for recombinantly producing such a fusion protein; and, lastly, it also relates to a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof.

Abstract: The invention concerns a biological organism comprising at least: (i) a nucleic acid coding for all or part of an antibody, said antibody being expressed at the surface of a host cell and capable of being fixed to a polypeptide present at the surface of a cytotoxic effector cell or of a T-helper lymphocyte and involved in the process of activating such a cell and (ii) a nucleic acid coding for all or part of a polypeptide involved in the stimulation of an immune response or in attraction to the site of expression and activation of cytotoxic effector cells or of T-helper lymphocytes, said polypeptide being selected among chemokines and co-stimulation molecules. The invention also concerns a host cell and a pharmaceutical composition containing said biological organism and their therapeutic or prophylactic uses.

Abstract: The present invention concerns a poxviral particle having a targeted infection specificity conferred by an heterologous ligand moiety present at the surface of said poxviral particle and capable of specifically recognizing and binding to an anti-ligand molecule localized at the surface of target cells. The present invention further relates to a vector comprising a nucleotide sequence encoding a chimeric polypeptide including such an heterologous ligand moiety and all or part of a natural poxviral surface polypeptide. The present invention additionally concerns compositions comprising said poxviral particle or said vector as well as their use for therapeutic and prophylactic purposes. The invention is of very special interest in gene therapy applications, in particular in preventing or treating cancer in mammals.

Abstract: Disclosed is an improved process for the preparation of ketoximes, especially ketoximes derived from branched chain ketones, wherein a ketone is reacted with a hydroxylamine salt in the presence of an alkanol, a heterogeneous base and up to about 5 weight percent, based on the weight of the ketone and alkanol, water.